Pear Therapeutics (PEAR) Tops Q1 EPS by 7c

Pear Therapeutics (NASDAQ: PEAR) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.4 million.

GUIDANCE:

Pear Therapeutics sees FY2022 revenue of $22 million.

For earnings history and earnings-related data on Pear Therapeutics (PEAR) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18